FDA grants priority review to Roche’s Lucentis for mCNV

ZURICH (Reuters) – The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday.

The ailment is a complication of severe near-sightedness that can lead to blindness, it added in a statement.

(Reporting by Michael Shields, editing by John Revill)